The Exceptional Parent, March 1st, 2000
Balancing the Promise With the Reality On September 17, 1999, four days after receiving a gene therapy infusion at the University of Pennsylvania, a young man from Arizona who had a genetic disease known as Ornithine Transcarbamylase Deficiency (OTC) died. His death--the first that could be directly linked to gene therapy--electrified the scientific community and triggered a national debate that will have a powerful impact on the future of gene therapy experiments and how they are approved and monitored. These are profound and important questions left unanswered, but for Jesse Gelsinger, the ...
HighBeam Research, Free Preview: 'GENE THERAPY.'... Full Membership required for unlimited access. Free 7-day trial.
Subscribers: HighBeam content is only available to HighBeam subscribers. Click the link above for more information.
